Press Releases
July 24, 2023
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer
All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
Interim Data Analysis anticipated in Early 2024
July 19, 2023
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
July 17, 2023
Panbela Announces Issuance of New Patent in Australia
Patent is for Claims of a Novel Process for the Production of SBP-101
July 10, 2023
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
June 28, 2023
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
June 26, 2023
Panbela Announces Poster Presentation at the Endocrine Society Meeting
Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
View/download poster presentation »
June 21, 2023
Panbela Announces Closing of Approximately $8.5 Million Public Offering
June 16, 2023
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
June 13, 2023
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
June 1, 2023
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting
Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
Events & Presentations